Abstract
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
CDC. HIV surveillance report, 2008. Vol 20. In: Division of HIV/AIDS Prevention NCfHA, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia, editor; 2010.
Campsmith ML, Rhodes PH, Hall HI, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr. 2010;53(5):619–24.
Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520–9.
Holtgrave DR, Hall HI, Rhodes PH, Wolitski RJ. Updated annual HIV transmission rates in the United States, 1977–2006. J Acquir Immune Defic Syndr. 2009;50(2):236–8.
Trends in HIV/AIDS diagnoses among men who have sex with men – 33 States, 2001–2006. MMWR Morb Mortal Wkly Rep. 2008;57(25):681–6.
Hall I, Helms D, Walker F, Belle E. Trends in HIV diagnoses and testing among U.S. adolescent and young adult males XVIII International AIDS Conference; 2010; Vienna, Austria; 2010.
Denning P, DiNenno E. Communities in crisis: is there a generalized HIV epidemic in impoverished urban areas of the United States? XVIII International AIDS Conference; 2010; Vienna, Austria; 2010.
UNAIDS. 2008 report on the global AIDS epidemic; 2008.
CDC. 2010 [cited; Available from: http://www.cdc.gov/hiv/topics/surveillance/resources/slides/general/index.htm. Last accessed August 19, 2010. Slides #14 ands #22.
Deeks SG, Gange SJ, Kitahata MM, et al. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009;49(10):1582–90.
Kousignian I, Abgrall S, Grabar S, et al. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency. Clin Infect Dis. 2008;46(2):296–304.
CDC. Late HIV testing – 34 states, 1996–2005. MMWR Morb Mortal Wkly Rep. 2009;58(24):661–5.
CDC. Late versus early testing of HIV – 16 Sites, United States, 2000–2003. MMWR Morb Mortal Wkly Rep. 2003;52(25):581–6.
CDC. Reported CD4+ T-lymphocyte results for adults and adolescents with HIV/AIDS-33 states, 2005. HIV/AIDS Surveill Suppl Rep. 2005;11(2).
Ogbuanu IU, Torres ME, Kettinger L, Albrecht H, Duffus WA. Epidemiological characterization of individuals with newly reported HIV infection: South Carolina, 2004–2005. Am J Public Health. 2007;99 Suppl 1:S111–7.
Keruly JC, Moore RD. Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis. 2007;45:1369–74.
Althoff KN, Gange SJ, Klein MB, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50(11):1512–20.
Expanded HIV testing and trends in diagnoses of HIV infection – District of Columbia, 2004–2008. MMWR Morb Mortal Wkly Rep. 59(24):737–41
Castel A, Samala R, Griffin A, et al. Monitoring the impact of expanded HIV testing in the District of Columbia using population-based HIV/AIDS surveillance data. 17th Conference on Retroviruses and Opportunistic Infections; 2010; San Francisco, CA, 2010.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2009: Department of Health and Human Services.
Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20(10):1447–50.
Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17.
CDC. Persons tested for HIV – United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57(31):845–9.
The national HIV/AIDS strategy for the United States and the national HIV/AIDS strategy: federal implementation plan. In: House W, editor. Washington, DC; 2010.
MacKellar DA, Valleroy LA, Secura GM, et al. Unrecognized HIV infection, risk behaviors, and perceptions of risk among young men who have sex with men - Opportunities for advancing HIV prevention in the third decade of HIV/AIDS. J Acquir Immune Defic Syndr. 2005;38(5):603–14.
CDC. HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men – five U.S. cities, June 2004–April 2005. MMWR Morb Mortal Wkly Rep. 2005;54(24):597–601.
CDC. Unrecognized HIV infection, risk behaviors, and perceptions of risk among young black men who have sex with men – six U.S. cities, 1994–1998. MMWR Morb Mortal Wkly Rep. 2002;51(33):733–6.
CDC. HIV transmission among black college student and non-student men who have sex with men – North Carolina, 2003. MMWR Morb Mortal Wkly Rep. 2004;53(32):731–4.
CDC. HIV transmission among black women – North Carolina, 2004. MMWR Morb Mortal Wkly Rep. 2005;54(4):89–94.
Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853–60.
Palella Jr FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34.
Patel K, Hernan MA, Williams PL, et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis. 2008;46(4):507–15.
Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007;21(6):685–92.
Ewings FM, Bhaskaran K, McLean K, et al. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS. 2008;22(1):89–95.
May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21(9):1185–97.
Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300(1):51–9.
Harrison KM, Song RG, Zhang XJ. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr. 2010;53(1):124–30.
Buchacz K, Baker RK, Palella FJ, et al. AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study. AIDS. 2010;24(10):1549–59.
Brooks JT, Kaplan JE, Holmes KK, Benson C, Pau A, Masur H. HIV-associated opportunistic infections-going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis. 2009;48(5):609–11.
Kourtis AP, Bansil P, Posner SF, Johnson C, Jamieson DJ. Trends in hospitalizations of HIV-infected children and adolescents in the United States: analysis of data from the 1994–2003 Nationwide Inpatient Sample. Pediatrics. 2007;120(2):e236–e43.
Buchacz K, Baker RK, Moorman AC, et al. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994–2005. AIDS. 2008;22(11):1345–54.
Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4(+) counts greater than 200 cells/mm(3). J Acquir Immune Defic Syndr. 2007;44(2):179–87.
Hooshyar D, Hanson DL, Wolfe M, Selik RM, Buskin SE, McNaghten AD. Trends in perimortal conditions and mortality rates among HIV-infected patients. AIDS. 2007;21:2093–100.
El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4 + count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–96.
Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815–26.
Sterne JAC, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352–63.
Funk MJ, Fusco JS, Cole SR, et al. HAART initiation and clinical outcomes: insights from the CASCADE cohort of HIV-1 seroconverters on “When to Start.” XVIII International AIDS Conference; 2010; Vienna, Austria; 2010.
Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008;22(7):841–8.
Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197(8):1133–44.
Lichtenstein KA, Armon C, Buchacz K, et al. Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr. 2008;47(1):27–35.
Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 2010;published ahead of print July 26 2010 [DOI: 10.1002/cncr.25311].
Uy J, Armon C, Buchacz K, Brooks JT, The HOPS Investigators. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr. 2009;51(4):450–3.
Phillips AN, Leen C, Wilson A, et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet. 2007;370(9603):1923–8.
Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-Infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148(10):728–U29.
Bedimo R. Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era. Curr HIV/AIDS Rep. 2008;5(3):140–9.
Simard EP, Pfeiffer RM, Engels EA. Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med. 2010;170(15):1337–45.
Polesel J, Franceschi S, Suligoi B, et al. Cancer incidence in people with AIDS in Italy. Int J Cancer. 2010;127(6):1437–45.
Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010;103(3):416–22.
Spradling PR, Richardson, Buchacz K, Moorman AC, Brooks JT, and the HIV Outpatient Study (HOPS) Investigators. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996–2007. J Viral Hepatitis. 2010;(published ahead of print doi:10.1111/j.1365-2893.2009.01249.x).
Spradling PR, Richardson JT, Buchacz K, et al. Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996–2007. J Acquir Immune Defic Syndr. 2010;53(3):388–96.
Crum-Cianflone N, Roediger MP, Eberly L, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One. 2010;5(4):e10106.
Tedaldi EM, Brooks JT, Weidle PJ, et al. Increased body mass index does not alter response to initial highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2006;43(1):35–41.
Vidrine DJ. Cigarette smoking and HIV/AIDS: health implications, smoker characteristics and cessation strategies. AIDS Educ Prev. 2009;21(3 Suppl):3–13.
Justice AC. Prioritizing primary care in HIV: comorbidity, toxicity, and demography. TopHIV Med. 2006;14(5):159–63.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Brooks, J.T., Chen, M. (2012). The HIV Epidemic in the USA: Current Trends, 2010. In: Sherman, K. (eds) HIV and Liver Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1712-6_1
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1712-6_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1711-9
Online ISBN: 978-1-4419-1712-6
eBook Packages: MedicineMedicine (R0)